Danish biotech (Nasdaq: GMAB) on Saturday revealed that US pharma major (AbbVie (NYSE: ABBV) has filed a complaint in the US ...

Insiders have been trading these 5 stocks: (($NVDA)), (($XOM)), (($ABBV)), (($UBER)) and (($ADBE)). Here is a breakdown of ...

Shares of AbbVie were recently trading for $212 apiece, and the company's total annual dividend amount (paid out over four ...

Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle) ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

As previously reported, Erste Group upgraded AbbVie (ABBV) to Buy from Hold. The firm notes AbbVie recently confirmed its ...

AbbVie (ABBV) closed the most recent trading day at $213.85, moving -0.29% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.07%. At the same time, ...

Bearish flow noted in AbbVie (ABBV) with 6,427 puts trading, or 1.5x expected. Most active are 4/11 weekly 210 puts and Mar-25 190 calls, with ...

AbbVie's Elahere maintains strong efficacy in the Phase 3 MIRASOL trial for ovarian cancer, with durable survival benefits ...

AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.